<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vfumed</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник Северо-Восточного федерального университета имени М.К. Аммосова. Vestnik of North-Eastern Federal University. Серия «Медицинские науки. Medical Sciences»</journal-title><trans-title-group xml:lang="en"><trans-title>Vestnik of North-Eastern Federal University. Medical Sciences</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2587-5590</issn><publisher><publisher-name>Северо-Восточный федеральный университет имени М.К. Аммосова</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25587/SVFU.2023.29.95.003</article-id><article-id custom-type="elpub" pub-id-type="custom">vfumed-249</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>НОВАЯ КОРОНАВИРУСНАЯ ИНФЕКЦИЯ И ТУБЕРКУЛЕЗ ЛЕГКИХ (на примере клинических случаев)</article-title><trans-title-group xml:lang="en"><trans-title>NEWCORONAVIRUS INFECTIONANDPULMONARYTUBERCULOSIS: CLINICAL CASES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гуляева</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gulyaeva</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гуляева Надежда Андреевна – канд. мед. наук, доцент кафедры «Инфекционные болезни, фтизиатрия и дерматовенерология», медицинский институт</p><p>677013 Россия, г. Якутск, ул. Ойунского, д. 27</p></bio><bio xml:lang="en"><p>Gulyaeva Nadezhda Andreevna – Candidate of Medical Sciences, Associate Professor, Department of Infectious Diseases, Phthisiology and Dermatovenerology</p><p>677013 Russia, Yakutsk, ul. Oyunskogo, 27</p></bio><email xlink:type="simple">NAGulyaeva15@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Прокопьев</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Prokopiev</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Прокопьев Егор Спиридонович – директор; гл. внешт. специалист-фтизиатр</p><p>677015 Россия, г. Якутск, П. Алексеева, 93 </p></bio><bio xml:lang="en"><p>Prokopiev Egor Spiridonovich – Director; chief freelance TB specialist</p><p>677015 Russia, Yakutsk, ul. P. Alekseeva, 93</p></bio><email xlink:type="simple">prokopeves@ftiz14.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федотова</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedotova</surname><given-names>L. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Федотова Любовь Петровна – врач-фтизиатр, отделение длительного наблюдения больных с хронической формой туберкулеза</p><p>677015 Россия, г. Якутск, П. Алексеева, 93</p></bio><bio xml:lang="en"><p>Fedotova Lyubov Petrovna – phthisiologist, department of long-term observation of patients with chronic tuberculosis</p><p>677015 Russia, Yakutsk, ul. P. Alekseeva, 93</p></bio><email xlink:type="simple">fedotovalp@ftiz.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Симонов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Simonov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Симонов Алексей Аркадьевич – зав. отделением длительного наблюдения больных с хронической формой туберкулеза</p><p>677015 Россия, г. Якутск, П. Алексеева, 93</p></bio><bio xml:lang="en"><p>Simonov Aleksey Arkadyevich – head of the department of long-term observation of patients with chronic tuberculosis</p><p>677015 Russia, Yakutsk, ul. P. Alekseeva 93</p></bio><email xlink:type="simple">simonovaa@ftiz14.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «СВФУ им. М.К. Аммосова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Medicine, M. K. Ammosov North- Eastern Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУ НПЦ «Фтизиатрия им. Е.Н. Андреева»; МЗ РС (Я)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E. N. Andreev Phthisiology Scientific and Practical Center; Ministry of Health of the Republic of Sakha (Yakutia)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУ НПЦ «Фтизиатрия имени Е.Н. Андреева»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E. N. Andreev Phthisiology Scientific and Practical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2023</year></pub-date><volume>0</volume><issue>4</issue><fpage>28</fpage><lpage>38</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гуляева Н.А., Прокопьев Е.С., Федотова Л.П., Симонов А.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Гуляева Н.А., Прокопьев Е.С., Федотова Л.П., Симонов А.А.</copyright-holder><copyright-holder xml:lang="en">Gulyaeva N.A., Prokopiev E.S., Fedotova L.P., Simonov A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.smnsvfu.ru/jour/article/view/249">https://www.smnsvfu.ru/jour/article/view/249</self-uri><abstract><p> В конце 2019 г. в Китайской Народной Республике (КНР) возникла вспышка новой коронавирусной инфекции SARS-CoV-2 с эпицентром в городе Ухане (провинция Хубэй). Всемирная организация здравоохранения (ВОЗ) 11 февраля 2020 г. определила официальное название болезни, вызванной новым коронавирусом, – COVID-19, а 11 марта 2020 г. объявила о начале пандемии, вызванной инфекцией SARS-CoV-2. COVID-19 – «молодое заболевание», что определяет важность изучения влияния хронической коморбидной патологии на риск инфицирования SARS-CoV-2, тяжесть течения и вероятность развития неблагоприятного исхода заболевания. Накопленные данные выделяют несколько групп риска тяжелого течения COVID-19. Это в первую очередь касается пациентов с наличием сопутствующей хронической патологии – диабета, сердечно-сосудистых заболеваний, ожирения и другие [5, 15]. Коинфекции, поражающие дыхательные пути, создают клинические дилеммы, а также диагностические и терапевтические проблемы. В данной статье представлены клинические примеры течения сочетания COVID-19 и туберкулеза легких. Новая коронавирусная инфекция протекала у больной с впервые выявленным туберкулезом тяжелее, чем у пациентки с хроническим туберкулезным процессом, что подтверждает различное влияние патологических процессов друг на друга. </p></abstract><trans-abstract xml:lang="en"><p>At the end of 2019, an outbreak of a new coronavirus infection, SARS-CoV-2, emerged in the People’s Republic of China with the epicenter in the city of Wuhan, Hubei Province. On February 11, 2020, the World Health Organization determined the official name of the disease caused by the new coronavirus – COVID-19, and on March 11, 2020, announced the beginning of a pandemic caused by the SARS-CoV-2 infection. COVID-19 is a “young disease”, which determines the importance of studying the influence of chronic comorbid pathology on the risk of infection with SARS-CoV-2, the severity of the course and the likelihood of developing an unfavorable outcome of the disease. Accumulated data identify several risk groups for severe COVID-19. First of all, this applies to patients with concomitant chronic pathologies: diabetes, cardiovascular diseases, obesity, and others [5, 15]. Coinfections affecting the respiratory tract pose clinical dilemmas as well as diagnostic and therapeutic challenges. This article presents clinical cases of the course of a combination of COVID-19 infection and pulmonary tuberculosis. The new coronavirus infection was more severe in a female patient with newly diagnosed tuberculosis than in a female patient with a chronic tuberculosis process, which confirms a different influence of the pathological processes on each other.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>новая коронавирусная инфекция</kwd><kwd>туберкулез</kwd><kwd>микобактерия туберкулеза</kwd><kwd>широкая лекарственная устойчивость</kwd><kwd>фиброзно-кавернозный туберкулез легких</kwd><kwd>лечение</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group xml:lang="en"><kwd>new coronavirus infection</kwd><kwd>tuberculosis</kwd><kwd>Mycobacterium tuberculosis</kwd><kwd>extensive drug resistance</kwd><kwd>fibrocavernous pulmonary tuberculosis</kwd><kwd>treatment</kwd><kwd>COVID-19</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">ВОЗ. Информационный бюллетень. Март 2021 // Социальные аспекты здоровья населения. ‒ 2021. – № 2 (67). ‒ С. 19.</mixed-citation><mixed-citation xml:lang="en">VOZ. Informacionnyj bjulleten’. Mart 2021 // Social’nye aspekty zdorov’ja naselenija. ‒ 2021. ‒ № 2 (67). ‒ S. 19.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 12 (21.09.2021)» (утв. Минздравом России).</mixed-citation><mixed-citation xml:lang="en">Ritacco V., Kantor I. N. Tuberculosis and COVID-19: a dangerous relationship. Tuberculosis y COVID-19: Una relación peligrosa // Medicina. – № 80. – S. 6. – R. 117 – 118.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ritacco V., Kantor I. N. Tuberculosis and COVID-19: a dangerous relationship. Tuberculosis y COVID-19: Una relación peligrosa // Medicina. – № 80. – S. 6. – Р. 117 – 118.</mixed-citation><mixed-citation xml:lang="en">Gao Y., Liu M., Chen Y., Shi S., Geng J., Tian J. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis // J. Med. Virol. ‒ 2021. ‒ Vol. 93, № 1. ‒ P. 194-196. https://doi.org/10.1002/jmv.26311.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gao Y., Liu M., Chen Y., Shi S., Geng J., Tian J. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis // J. Med. Virol. ‒ 2021. ‒ Vol. 93, № 1. ‒ P. 194 – 196. https://doi.org/10.1002/jmv.26311.</mixed-citation><mixed-citation xml:lang="en">Koupaei M., Naimi A., Moafi N., Mohammadi P., Tabatabaei F. S., Ghazizadeh S., Heidary M., Khoshnood S. Clinical characteristics, diagnosis, treatment, and mortality rate of TB/COVID-19 coinfectetd patients: A systematic review // Front. Med. (Lausanne). ‒ 2021. ‒ Vol. 8. ‒ P. 740593. https://doi.org/10.3389/fmed.2021.740593.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Koupaei M., Naimi A., Moafi N., Mohammadi P., Tabatabaei F. S., Ghazizadeh S., Heidary M., Khoshnood S. Clinical characteristics, diagnosis, treatment, and mortality rate of TB/COVID-19 coinfectetd patients: A systematic review // Front. Med. (Lausanne). ‒ 2021. ‒ Vol. 8. ‒ P. 740593. https://doi.org/10.3389/fmed.2021.740593.</mixed-citation><mixed-citation xml:lang="en">Shen H., Chen Z. W. The crucial roles of Th17-related cytokines/signal pathways in M. tuberculosis infection // Cell. Mol. Immunol. – 2018. – Vol. 15, № . 3. – P. 216 – 225. https://doi.org/10.1038/cmi.2017.128.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shen H., Chen Z. W. The crucial roles of Th17-related cytokines/signal pathways in M. tuberculosis infection // Cell. Mol. Immunol. – 2018. – Vol. 15, № . 3. – P. 216 – 225. https://doi.org/10.1038/cmi.2017.128.</mixed-citation><mixed-citation xml:lang="en">Yongang Z., Binqing F., Xiaohu Zh., Dongsheng W., Changcheng Z., Yingjie Q., Rui S., Zhigang T., Xiaoling X., Haiming W. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus // BioRxiv. – 2020.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Yongang Z., Binqing F., Xiaohu Zh., Dongsheng W., Changcheng Z., Yingjie Q., Rui S., Zhigang T., Xiaoling X., Haiming W. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus // BioRxiv. – 2020</mixed-citation><mixed-citation xml:lang="en">Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L., Chen L., Li M., Liu Y., Wang G., Yuan Z., Feng Z., Zhang Y., Wu Y., Chen Y. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19) // Front. Immunol. ‒ 2020. ‒ Vol. 11. ‒ P. 827. https://doi.org/10.3389/fimmu.2020.00827.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L., Chen L., Li M., Liu Y., Wang G., Yuan Z., Feng Z., Zhang Y., Wu Y., Chen Y. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19) // Front. Immunol. ‒ 2020. ‒ Vol. 11. ‒ P. 827. https://doi.org/10.3389/fimmu.2020.00827.</mixed-citation><mixed-citation xml:lang="en">Etna M. P., Giacomini E., Severa M., Coccia E. M. Proand anti-inflammatory cytokines in tuberculosis: a two-edged sword in TB pathogenesis // Semin. Immunol. – 2014. – Vol. 26, № 6. – P. 543 – 551. https://doi. org/10.1016/j. smim.2014.09.011.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Etna M. P., Giacomini E., Severa M., Coccia E. M. Proand anti-inflammatory cytokines in tuberculosis: a two-edged sword in TB pathogenesis // Semin. Immunol. – 2014. – Vol. 26, № 6. – P. 543 – 551. https://doi.org/10.1016/j. smim.2014.09.011.</mixed-citation><mixed-citation xml:lang="en">Mack U., Migliori G. B., Sester M., Rieder H. L., Ehlers S., Goletti D., Bossink A., Magdorf K., Hölscher C., Kampmann B., Arend S. M., Detjen A., Both G., Zellweger J. P., Milburn H., Diel R., Ravn P., Cobelens F., Cardona P. J., Kan B. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement // Eur. Respir. J. – 2009. – Vol. 33. – № 5. – R. 956 – 973. https://doi.org/10.1183/09031936.00120908.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mack U., Migliori G. B., Sester M., Rieder H. L., Ehlers S., Goletti D., Bossink A., Magdorf K., Hölscher C., Kampmann B., Arend S. M., Detjen A., Both G., Zellweger J. P., Milburn H., Diel R., Ravn P., Cobelens F., Cardona P. J., Kan B. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement // Eur. Respir. J. – 2009. – Vol. 33. – № 5. – Р. 956 – 973. https://doi.org/10.1183/09031936.00120908.</mixed-citation><mixed-citation xml:lang="en">Mousquer G. T., Peres A., Fiegenbaum M. Pathology of TB/COVID-19 Co-Infection: The phantom menace // Tuberculosis. – 2021. – № 126. https://doi.org/10.1016/j.tube.2020.102020.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mousquer G. T., Peres A., Fiegenbaum M. Pathology of TB/COVID-19 Co-Infection: The phantom menace // Tuberculosis. – 2021. – № 126. https://doi.org/10.1016/j.tube.2020.102020.</mixed-citation><mixed-citation xml:lang="en">Davies M. HIV and risk of COVID-19 death: a population cohort study from the // Western Cape Province, South Africa // The preprint server for health sciences. – 2020. ‒ № 3. https://doi.org/10.1101/2020.07.02.2014 5185.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Davies M. HIV and risk of COVID-19 death: a population cohort study from the // Western Cape Province, South Africa // The preprint server for health sciences. – 2020. ‒ № 3. https://doi.org/10.1101/2020.07.02.2014 5185.</mixed-citation><mixed-citation xml:lang="en">Tadolini M., Codecasa L. R., García-García J. M., Blanc F. X., Borisov S., Alffenaar J. W., Andréjak C., Bachez P., Bart P. A., Belilovski E., Cardoso-Landivar J., Centis R., D’Ambrosio L., De Souza-Galvão M. L., Dominguez-Castellano A., Dourmane S., Fréchet Jachym M., Froissart A., Giacomet V., Goletti D., Grard S., Gualano G., IzadifarA., Le Du D., Royo M., Mazza-Stalder J., Motta I., Ong CWM, Palmieri F., Rivière F., Rodrigo T., Silva D. R., Sánchez-Montalvá A., Saporiti M., Scarpellini P., Schlemmer F., Spanevello A., Sumarokova E., Tabernero E., Tambyah P. A., Tiberi S., Torre A., Visca D., Zabaleta Murguiondo M., Sotgiu G., Migliori G. B. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases // Eur. Respir. J. – 2020. – Vol. 56, № 1. https://doi.org/10.1183/13993003.01398-2020.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tadolini M., Codecasa L. R., García-García J. M., Blanc F. X., Borisov S., Alffenaar J. W., Andréjak C., Bachez P., Bart P. A., Belilovski E., Cardoso-Landivar J., Centis R., D’Ambrosio L., De Souza-Galvão M. L., Dominguez-Castellano A., Dourmane S., Fréchet Jachym M., Froissart A., Giacomet V., Goletti D., Grard S., Gualano G., Izadifar A., Le Du D., Royo M., Mazza-Stalder J., Motta I., Ong CWM, Palmieri F., Rivière F., Rodrigo T., Silva D. R., Sánchez-Montalvá A., Saporiti M., Scarpellini P., Schlemmer F., Spanevello A., Sumarokova E., Tabernero E., Tambyah P. A., Tiberi S., Torre A., Visca D., Zabaleta Murguiondo M., Sotgiu G., Migliori G. B. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases // Eur. Respir. J. – 2020. – Vol. 56, № 1. https://doi.org/10.1183/13993003.01398-2020.</mixed-citation><mixed-citation xml:lang="en">Torun S., Ozkaya S., Şen N., Kanat F., Karaman I., Yosunkaya S., Sengoren Dikis O., Asan A., Aydogan Eroglu S., Semih Atal S., Ayten O., Aksel N., Ermiş H., Özçelik N., Demirelli M., Kara I., Sümer S., Marakoğlu K., Üzer F., Uyar Y., Çiçek T., E Ünsal Z., Vatansev H., Botan Yildirim B., Kuruoğlu T., Atilla A., Ersoy Y., Kandemir B., Durduran Y., Goksin Cihan F., Demirbaş N., Yıldırım F., Tatar D., Akcay M. S. The Relationship between COVID-19 Severity and Bacillus Calmette-Guérin (BCG) / Mycobacterium tuberculosis exposure history in healthcare workers: a multi-center study // Pathog. Glob. Health. – 2021. – Vol. 115, № . 6. – P. 405 – 411. https://doi.org/10.1080/20477724.2021.1927605.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Torun S., Ozkaya S., Şen N., Kanat F., Karaman I., Yosunkaya S., Sengoren Dikis O., Asan A., Aydogan Eroglu S., Semih Atal S., Ayten O., Aksel N., Ermiş H., Özçelik N., Demirelli M., Kara I., Sümer S., Marakoğlu K., Üzer F., Uyar Y., Çiçek T., E Ünsal Z., Vatansev H., Botan Yildirim B., Kuruoğlu T., Atilla A., Ersoy Y., Kandemir B., Durduran Y., Goksin Cihan F., Demirbaş N., Yıldırım F., Tatar D., Akcay M. S. The Relationship between COVID-19 Severity and Bacillus Calmette-Guérin (BCG) / Mycobacterium tuberculosis exposure history in healthcare workers: a multi-center study // Pathog. Glob. Health. – 2021. – Vol. 115, № . 6. – P. 405 – 411. https://doi.org/10. 1080/20477724.2021.1927605.</mixed-citation><mixed-citation xml:lang="en">Il’ina N.A., Slepcova S.S., D’jachkovskaja P.S., Slepcov S.S. PREDIKTORY TJaZhESTI TEChENIJa NOVOJ KORONAVIRUSNOJ INFEKCII COVID-19 V RESPUBLIKE SAHA (JaKUTIJa) // Sovremennye problemy nauki i obrazovanija. – 2022. – № 2.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ильина Н.А., Слепцова С.С., Дьячковская П.С., Слепцов С.С. Предикторы тяжести течения новой коронавирусной инфекции covid-19 в Республике Саха (Якутия) // Современные проблемы науки и образования. – 2022. – № 2.</mixed-citation><mixed-citation xml:lang="en">Kuznecova A.M., Slepcova S.S. NOVAJa KORONAVIRUSNAJa INFEKCIJa COVID-19 I OSTRYJ INFARKT MIOKARDA: KLINIChESKIJ SLUChAJ. Vestnik Severo-Vostochnogo federal’nogo universiteta imeni M.K. Ammosova. Serija: Medicinskie nauki. 2023; (1): 58 – 65.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Кузнецова А.М., Слепцова С.С. Новая коронавирусная инфекция COVID-19 и острый инфаркт миокарда: клинический случай. Вестник Северо-Восточного федерального университета имени М.К. Аммосова. Серия: Медицинские науки. 2023; (1): 58 – 65.</mixed-citation><mixed-citation xml:lang="en">Savinceva E.V., Isaeva P.V., Nizamova G.F. Tuberkulez i COVID-19: medicinskie i social’nye aspekty. Tuberkulez i bolezni legkih. 2022; 100(3): 13 – 17. https://doi.org/10.21292/2075-1230-2022-100-3-13-17</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Савинцева Е.В., Исаева П.В., Низамова Г.Ф. Туберкулез и COVID-19: медицинские и социальные аспекты. Туберкулез и болезни легких. 2022; 100(3): 13 – 17. https://doi.org/10.21292/2075-1230-2022-1003-13-17</mixed-citation><mixed-citation xml:lang="en">Slepcova S.S., Borisova E.A., Tarasova V.E., Malinnikova E.Ju. Opyt raboty infekcionnoj sluzhby Respubliki Saha (Jakutija)v period pandemii novoj koronovirusnoj infekcii. Infekcionnye bolezni: novosti, mnenija, obuchenie. 2020. T9. № 3 (34). S. 30 – 35.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Слепцова С.С., Борисова Е.А., Тарасова В.Е., Малинникова Е.Ю. Опыт работы инфекционной службы Республики Саха (Якутия) в период пандемии новой коронавирусной инфекции. Инфекционные болезни: новости, мнения, обучение. 2020. Т9. № 3 (34). С.30 – 35.</mixed-citation><mixed-citation xml:lang="en">Слепцова С.С., Борисова Е.А., Тарасова В.Е., Малинникова Е.Ю. Опыт работы инфекционной службы Республики Саха (Якутия) в период пандемии новой коронавирусной инфекции. Инфекционные болезни: новости, мнения, обучение. 2020. Т9. № 3 (34). С.30 – 35.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
